

Radiation Biology and Radiation Protection

Prof. Jolyon Hendry
Manchester, U.K.



ICRP Committee 1 in Amsterdam, Netherlands, October 2010

Tissue reactions (Deterministic effects)

- ICRP 41 (1984): non-stochastic injury in populations of cells
- ICRP 60 (1991): deterministic effects, causally determined by preceding events i.e. the dose
- ICRP 103 (2007): tissue reactions (deterministic effects), subject to biological response modifiers (dose modifying factors 1.1 to 2)

Volume 14 No. 3 1984

Annals of the ICRP

ICRP PUBLICATION 41

Nonstochastic Effects of Ionizing Radiation



Pergamon Press OXFORD · NEW YORK · FRANKFURT

Volume 36 Nos. 1-2 2006

ISSN 0146-6453
ISBN 008-045-0636

ICRP

Annals of the ICRP


ICRP Publication 100X

Early and Late Effects of Radiation in Normal Tissues and Organs: Threshold Doses for Tissue Reactions in a Radiation Protection Context







9/4/2011 9:51

Time of expression of radiation injury in rodents




Rapidly proliferating tissues (short turnover time) express radiation injury much earlier than **slowly proliferating** tissues

Fiona Stewart and Bert van der Kogel, 2002




Radiation injury in early-responding tissues with “stem cell” population



- Time of expression of injury depends on lifespan of differentiated (non-proliferating) cells; *independent of dose*.
- Maximum injury and rate of recovery depend on level of cell killing in stem cell compartment; *dose dependent*.

Adapted from Wolfgang Dörr/ Fiona Stewart

Pathogenesis of late radiation injury




- Time of expression of injury depends on level of cell kill; *dose & time dependent*.
- Numerous cytokine responses contribute to, & modify, extent of radiation injury.
- “Consequential” late effects in mucosal tissues after severe early injury.
- “Functional” radiosensitivity depends on tissue architecture and reserve capacity.

Adapted from Wolfgang Dörr/ Fiona Stewart

Threshold dose

- Maximum dose at which the effect does not occur (ICRP principle).
- The lowest dose at which a statistically-significant positive dose-response can be detected (Epidemiology).

Threshold doses (TD) and sampling uncertainties




.....a linear dose-response relationship will not suddenly dive to zero immediately below the lowest level at which a statistically significant excess is observed.

Professor Sir Richard Doll, 1997

Threshold dose choices

- Maximum dose at which the effect does not occur (ICRP principle).
- The lowest dose at which a statistically-significant positive dose-response can be detected (Epidemiology).
- Dose resulting in only 1% incidence of defined tissue reactions, chosen for 'practical' purposes (ICRP, 2007).
 - Less than 1% : greater extrapolation, less accurate.
 - More than 1% : less extrapolation, more accurate, but unacceptable.
 - Context needs to be considered i.e. public, workers, medical practice.

Threshold dose (TD)




ICRP 41, 60, 103, and Tissue Reactions report

Effect	Organ/tissue	Time to develop effect	Absorbed dose ^b resulting in about 1% incidence		
			Acute exposure (Gy)	^c Highly fractionated (2 Gy per fraction) or equivalent protracted exposures (Gy)	Annual (chronic) dose rate for many years (Gy y ⁻¹)
Mortality					
Bone marrow syndrome:					
- without medical care	Bone marrow	30-60 days	~1	10	NA
- with good medical care	Bone marrow	30-60 days	2-3	? >10	NA
Gastro-intestinal syndrome:					
- without medical care	Small intestine	6-9 days	~6	NA	NA
- with conventional medical care	Small intestine	6-9 days	>6	40	NA
Pneumonitis –mean lung dose	Lung	1-7 months	6.5	15	NA
Cardiovascular disease – whole body exposure	Heart	>10-15 years	~0.5	~0.5	~0.5 divided by years duration
Cerebrovascular disease	Carotid artery	>10 years	~0.5	~0.5	~0.5 divided by years duration

Mortality

Threshold doses (ED₁):

Acute, Fractionated, Chronic exposures



? ? ?


Effect	Organ/tissue	Time to develop effect	Absorbed dose ^a resulting in about 1% incidence		
			Acute exposure (Gy)	^b Highly fractionated (2 Gy per fraction) or equivalent protracted exposures (Gy)	Annual (chronic) dose rate for many years (Gy y ⁻¹)
<i>Morbidity:</i>					
Morbidity					
Temporary sterility	Testes	3-9 weeks	~0.1	NA	0.4
Permanent sterility	Testes	3 weeks	~6	<6	2.0
Permanent sterility	Ovaries	< 1 week	~3	6.0	>0.2
Depression of haemopoiesis	Bone marrow	3-7 days	~0.5	10-14Gy	>0.4
Digestive system					
	Salivary glands	1 week	NA	<20	NA
	Oesophagus	3-8 months	NA	55	NA
	Stomach	2 years	NA	50	NA
	Small intestine	1.5 years	NA	45	NA
	Colon	2 yaers	NA	50	NA
	Rectum	1 year	NA	60	NA
	Liver	2 weeks	NA	<30-32	NA
Main phase of skin reddening	Skin (large areas)	1-4 weeks	<3-6	30	NA
Skin burns	Skin (large areas)	2-3 weeks	5-10	35	NA
Temporary hair loss	Skin	2-3 weeks	~4	NA	NA
Late atrophy	Skin (large areas)	> 1 year	10	40	NA
Telangiectasia @ 5 years	Skin (large areas)	> 1 year	10	40	NA
Cataract (visual impairment)	Eye	>20 years	~0.5	~0.5	~0.5 divided by years duration ^c
Urinary Tract	Kidney	> 1 year	7-8	18	NA
	Bladder	> 6 months	15	55	NA
	Ureters	>6 months	NA	55-60	NA
Musculoskeletal system	Adult bone	> 1 year	NA	50	NA
	Growing bone	< 1 year	NA	25	NA
	Muscle	Several years	NA	55	NA
Endocrine system	Thyroid	?	NA	>18	NA

Morbidity


Threshold doses (ED₁):

Acute,
Fractionated,
Chronic exposures

? ? ?




Multi-fractionated doses or low-dose-rate



Threshold Dose dependent on Fractionation/ Dose-rate because:

- Gradual reduction in the quadratic component
- Repair, Repopulation, Adaptation
- If short follow-up time, not all injury expressed and threshold dose high

Multi-fractionated doses or low-dose-rate



Why would the Threshold Dose be independent of Fractionation/ Dose-rate?

- Greater statistical uncertainties below 0.5 Gy
- Response at low doses due to irreparable and persistent radiation lesions
- Different target cell populations at risk for low doses versus higher doses

Organ	Agent	DMF ^a
<i>Bone marrow:</i>		
Early reactions	Antibiotics Granulocyte-macrophage Colony-stimulating-factor	1.2–1.8 (rodents and monkeys)
<i>Intestine:</i>		
Early reactions	Antibiotics Interleukin-1 Angiogenic growth factors Interleukin-11, Transforming growth factor-β3	1.1–1.4 (rats) 1.1 1.1 (mice) ^b >1.0
Late reactions	Low molecular weight diet Antiplatelet Clopidogrel	>1.0 (rats) >1.0 (rats) ^c
<i>Skin:</i>		
Alopecia	Prostaglandin E2	1.2–1.5
Early reactions	γ-linolenic acid	1.1–1.2 (pigs)
Late reactions	γ-linolenic acid Blood-cell modifiers Cu/Zn/Mn-SOD	1.1–1.2 (pigs) 1.4 >1.0 (pigs) ^d
<i>Oral mucosa:</i>		
Early reactions	Keratinocyte growth factor	about 2.0
<i>Lung:</i>		
Pneumonitis	Interleukin-1, Tumour necrosis factor-α	>1.0 >1.0
<i>Spinal cord:</i>		
Late reactions	Vasoactive agents	1.1 (rats)
<i>Kidney:</i>		
Late reactions	Captopril, angiotensin II blockers	>1.0 (rats)

Dose modifying factors
(DMF) in mice and other
species (updated from
Hendry, 1994)

^a DMF = ratio of radiation doses with or without the protective agent, causing the same level of effect.

>1.0 indicates that the observed protection could not be quantified in terms of a DMF value, because dose-response relationships were not available. Reactions were assessed as less severe for combined radiation and agent.

^b Okunieff et al. (1998).

^c Wang et al. (2002).

^d Lefaix et al. (1996).

Breaking News: Biological Response Modifiers



LITTLE ROCK – The University of Arkansas for Medical Sciences (UAMS) has signed a contract with the federal Biomedical Advanced Research and Development Authority (BARDA) to proceed with *“advanced development of a promising treatment for use in radiological or nuclear emergency situations.”*


The initial award is for \$4.5 million over two years rising to nearly \$13 million.

UAMS’ Martin Hauer-Jensen, M.D., Ph.D., an internationally renowned radiation researcher, will lead the evaluation of *the drug, SOM230, or pasireotide, to treat gastrointestinal injuries* after radiological or nuclear accidents or terrorist attacks.

The intestine and bone marrow are most susceptible to radiation because of their rapidly proliferating cells. *Treatments exist for irradiated bone marrow but not for the intestine.*

Gray and Sievert Units

Stochastic effects: Sv



Tissue reactions: Gy or RBE.Gy